Rep. April McClain Delaney Purchases Shares of Labcorp Holdings Inc. (NYSE:LH)

Representative April McClain Delaney (Democratic-Maryland) recently bought shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on March 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Labcorp stock on February 4th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of EMCOR Group (NYSE:EME) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/27/2026.
• Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 2/25/2026.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of CDW (NASDAQ:CDW) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/23/2026.

Labcorp Stock Performance

Shares of LH traded up $3.74 on Tuesday, reaching $270.59. The company’s stock had a trading volume of 522,575 shares, compared to its average volume of 649,723. The stock’s 50 day simple moving average is $273.07 and its two-hundred day simple moving average is $269.74. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. The stock has a market capitalization of $22.30 billion, a P/E ratio of 25.87, a PEG ratio of 1.82 and a beta of 1.01. Labcorp Holdings Inc. has a 12-month low of $209.38 and a 12-month high of $293.72.

Labcorp (NYSE:LH) last announced its earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. During the same period in the prior year, the company earned $3.45 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Research analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Friday, February 27th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Institutional Trading of Labcorp

A number of institutional investors and hedge funds have recently modified their holdings of LH. Brighton Jones LLC purchased a new position in Labcorp in the 4th quarter valued at about $991,000. Integrated Wealth Concepts LLC increased its position in shares of Labcorp by 7.9% during the first quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock worth $565,000 after purchasing an additional 177 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Labcorp by 52.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock valued at $82,353,000 after purchasing an additional 121,304 shares during the last quarter. Savant Capital LLC raised its stake in Labcorp by 3.4% in the 2nd quarter. Savant Capital LLC now owns 5,034 shares of the medical research company’s stock valued at $1,321,000 after purchasing an additional 164 shares during the last quarter. Finally, Wedbush Securities Inc. purchased a new position in Labcorp in the 2nd quarter valued at $256,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

LH has been the topic of a number of recent research reports. Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Piper Sandler upped their price target on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Robert W. Baird raised their price objective on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Finally, Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $304.82.

Insider Buying and Selling at Labcorp

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president directly owned 2,579 shares of the company’s stock, valued at $734,782.89. This trade represents a 17.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Adam H. Schechter sold 8,705 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 16,113 shares of company stock worth $4,547,450. Company insiders own 0.84% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.